| Hizentra (human immune globulin subcutaneous 20%) / CSL Behring |
2017-002024-24: Systematic reduction in dosage of subcutanoeus immunoglobulin in patients with chronic inflammatory neuropathy Standardiseret aftrapning af dosis af subkutan immunglobulin hos patienter med kronisk inflammatorisk nervebetændelse |
|
|
| Ongoing | 4 | 60 | Europe | Gammanorm, Hizentra, Subcuvia, Solution for injection/infusion, Gammanorm, Hizentra, Subcuvia | Aarhus Unversity Hospital, Danish Regions | Chronic inflammatory demyelinating polyneuroapthy Kronisk inflammatorisk demyeliniserende polyneuropati, Chronic inflammatory polyneuropathy Kronisk immunmedeieret nervebetændelse, Diseases [C] - Nervous System Diseases [C10] | | | | |
2018-003592-34: Subcutaneous versus intravenous administration of immunoglobulin in newly diagnosed patients with chronic inflammatory neuropathy Subkutan versus intravenøs behandling med immunglobulin hos nydiagnosticerede patienter med kronisk inflammatorisk nervebetændelse |
|
|
| Not yet recruiting | 4 | 60 | Europe | Hizentra, Privigen, Concentrate for solution for injection/infusion, Hizentra, Privigen | Aarhus University Hospital, CSL Behring AB | Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Kronisk inflammaotrisk demyeliniserende polyneuropati (CIDP), Chronic inflammatory neuropathy Kronisk inflammatorisk nervebetændelse, Diseases [C] - Nervous System Diseases [C10] | | | | |
NCT05193552: Usage of Spirometry in Managing IgG Therapy in CVID With Airway Disease |
|
|
| Recruiting | 4 | 22 | US | Hizentra, subcutaneous gammaglobulin therapy | University of Alabama at Birmingham | Common Variable Immunodeficiency | 12/25 | 12/26 | | |
SCIG-MG, NCT02774239: A Pilot Trial To Assess The Feasibility And Efficacy Of SCIG In Patients With MG Exacerbation |
|
|
| Completed | 3 | 26 | Canada | Human normal immunoglobulin G (IgG), Hizentra® | University of Alberta, CSL Behring | Myasthenia Gravis | 10/22 | 10/22 | | |
| Active, not recruiting | 3 | 126 | Europe, Japan, US, RoW | human immunoglobulin G, IgPro20, Hizentra, Placebo | CSL Behring, CSL Behring LLC, 1020 First Avenue, King of Prussia, PA 19406 | Dermatomyositis | 05/28 | 05/28 | | |
NCT06524739: Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS |
|
|
| Recruiting | 3 | 177 | Canada, US | IgPro20, HIZENTRA®, Placebo | CSL Behring | Post-COVID Postural Orthostatic Tachycardia Syndrome | 09/27 | 09/27 | | |
| Active, not recruiting | 1 | 20 | US | Intravenous immune globulin G, Privigen, IVIG, Subcutaneous immune globulin G, Hizentra, SCIG | Rutgers, The State University of New Jersey | CIDP, Immunoglobulin Deficiency, Chronic Inflammatory Demyelinating Polyneuropathy | 12/25 | 12/25 | | |
| Recruiting | N/A | 100 | Europe | Hizentra, IgPro20 | CSL Behring | Chronic Inflammatory Demyelinating Polyneuropathy | 12/27 | 12/27 | | |
